BMRN · Biomarin Pharmaceutical Inc
$67.36
-1.17 (-1.71%)
At close · Aug 14
Market Cap
$13.04B
Shares
193.57M
Biomarin Pharmaceutical Inc Earnings Call Transcripts
Every quarterly earnings call for Biomarin Pharmaceutical Inc (BMRN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.6%
$505.34M
−$6.65M
'22 Q3
22-10-26
▲19.5%
$537.54M
−$249,000
'22 Q4
23-02-27
▲14.8%
$596.41M
$50.85M
'23 Q1
23-04-26
▲11.5%
$595.27M
$56.04M
'23 Q2
23-07-31
▲15%
$581.33M
$40.38M
'23 Q3
23-11-01
▲20.2%
$646.21M
$20.38M
'23 Q4
24-02-22
▲8.8%
$648.83M
$88.66M
'24 Q1
24-04-24
▲19.6%
$712.03M
$107.17M
'24 Q2
24-08-05
▲28.3%
$745.74M
$106.08M
'24 Q3
24-10-29
▲15.6%
$747.31M
$124.94M
'24 Q4
25-02-19
▲14.8%
$745.14M
$185.69M
'25 Q1
25-05-16
▲15.9%
$825.41M
$240.53M
'25 Q2
25-08-04
▲4.1%
$776.13M
−$30.74M
'25 Q3
25-10-27
▲17%
$874.57M
−$46.57M
'25 Q4
26-02-23
▲2.8%
$766.21M
$105.53M
'26 Q1
26-05-04
LATEST
▲19.9%
$989.71M
$44.76M
'26 Q2
26-08-06
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
BioMarin Pharmaceutical Second Quarter 2026 Conference Call
Confident tone
Voxzogo (Vosoritide) Performance and Expansion
Galafold (Fabry Disease) Commercial Outlook
Amicus Acquisition Integration
Revenue
$989.71M
▲ 19.9% YoY Diluted EPS
$0.23
▼ 81.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
Biomarin Pharmaceutical Inc Q1 FY2026 Earnings Call
Confident tone
Voxzogo commercial momentum
Amicus acquisition and integration
Enzyme Therapies growth
Revenue
$766.21M
▲ 2.8% YoY Diluted EPS
$0.54
▼ 43.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Biomarin Pharmaceutical Inc Q4 FY2025 Earnings Call
Confident tone
Revenue growth and franchise performance
Voxzogo label expansion (hypochondroplasia)
Inorganic growth via acquisitions
Revenue
$874.57M*
▲ 17% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-27
Biomarin Pharmaceutical Inc Q3 FY2025 Earnings Call
Positive tone
VOXZOGO growth and achondroplasia franchise
Hypochondroplasia label expansion
Enzyme Therapies business unit
Revenue
$776.13M
▲ 4.1% YoY Diluted EPS
$-0.16
▼ 129.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biomarin Pharmaceutical Inc Q2 FY2025 Earnings Call
Confident tone
Revenue growth and full-year guidance raise
BMN 333 (long-acting achondroplasia therapy) Phase II/III
BMN 401 / Inozyme acquisition and ENERGY III trial
Revenue
$825.41M
▲ 15.9% YoY Diluted EPS
$1.23
▲ 123.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-16
Biomarin Pharmaceutical Inc Q1 FY2025 Earnings Call
Confident tone
VOXZOGO franchise
Pipeline and R&D
Revenue and earnings growth
Revenue
$745.14M
▲ 14.8% YoY Diluted EPS
$0.95
▲ 106.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Biomarin Pharmaceutical Inc Q4 FY2024 Earnings Call
Confident tone
VOXZOGO growth and franchise leadership
Pipeline catalysts and clinical data
Enzyme therapy franchise durability
Revenue
$747.31M*
▲ 15.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Biomarin Pharmaceutical Inc Q3 FY2024 Earnings Call
Confident tone
VOXZOGO growth and Skeletal Conditions franchise
BMN 333 long-acting CNP development
Enzyme Therapies portfolio performance
Revenue
$745.74M
▲ 28.3% YoY Diluted EPS
$0.55
▲ 161.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biomarin Pharmaceutical Inc Q2 FY2024 Earnings Call
Confident tone
VOXZOGO commercial momentum and label expansion
ROCTAVIAN strategic reset and focused launch
Revenue timing dynamics between orders and patients
Revenue
$712.03M
▲ 19.6% YoY Diluted EPS
$0.55
▲ 89.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biomarin Pharmaceutical Inc Q1 FY2024 Earnings Call
Positive tone
Voxzogo growth and label expansion
Roctavian commercial challenges
Investor Day strategy reveal
Revenue
$648.83M
▲ 8.8% YoY Diluted EPS
$0.46
▲ 70.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Biomarin Pharmaceutical Inc Q4 FY2023 Earnings Call
Confident tone
VOXZOGO commercial acceleration
Financial performance and 2024 guidance
ROCTAVIAN launch and uptake
Revenue
$646.21M*
▲ 20.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Biomarin Pharmaceutical Inc Q3 FY2023 Earnings Call
Revenue
$581.33M
▲ 15% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-31
Biomarin Pharmaceutical Inc Q2 FY2023 Earnings Call
Revenue
$595.27M
▲ 11.5% YoY Diluted EPS
$0.29
▲ 93.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Biomarin Pharmaceutical Inc Q1 FY2023 Earnings Call
Revenue
$596.41M
▲ 14.8% YoY Diluted EPS
$0.27
▼ 57.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Biomarin Pharmaceutical Inc Q4 FY2022 Earnings Call
Revenue
$537.54M*
▲ 19.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Biomarin Pharmaceutical Inc Q3 FY2022 Earnings Call
Revenue
$505.34M
▲ 23.6% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-25
Biomarin Pharmaceutical Inc Q2 FY2022 Earnings Call
Revenue
$533.80M
▲ 6.4% YoY Diluted EPS
$0.15
▲ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Biomarin Pharmaceutical Inc Q1 FY2022 Earnings Call
Revenue
$519.36M
▲ 6.9% YoY Diluted EPS
$0.63
▲ 600% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Biomarin Pharmaceutical Inc Q4 FY2021 Earnings Call
Revenue
$449.81M*
▼ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Biomarin Pharmaceutical Inc Q3 FY2021 Earnings Call
Revenue
$408.74M
▼ 14.3% YoY Diluted EPS
$-0.20
▼ 105% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Biomarin Pharmaceutical Inc Q2 FY2021 Earnings Call
Revenue
$501.69M
▲ 16.8% YoY Diluted EPS
$0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Biomarin Pharmaceutical Inc Q1 FY2021 Earnings Call
Revenue
$486.03M
▼ 3.2% YoY Diluted EPS
$0.09
▼ 79.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biomarin Pharmaceutical Inc Q4 FY2020 Earnings Call
Revenue
$452.12M*
▼ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biomarin Pharmaceutical Inc Q3 FY2020 Earnings Call
Revenue
$476.78M
▲ 3.4% YoY Diluted EPS
$4.01
▲ 1236.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Biomarin Pharmaceutical Inc Q2 FY2020 Earnings Call
Revenue
$429.49M
▲ 10.8% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Biomarin Pharmaceutical Inc Q1 FY2020 Earnings Call
Revenue
$502.07M
▲ 25.3% YoY Diluted EPS
$0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Biomarin Pharmaceutical Inc Q4 FY2019 Earnings Call
Revenue
$454.44M*
▲ 28.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
543 filings
511 filers
Visit website
Investor relations